NCT00266240View on ClinicalTrials.gov

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

GK Activator (2)

Escalating doses po bid

DRUG

Placebo

po bid

Trial Locations (44)

1083

Budapest

1088

Budapest

1233

Sofia

1303

Sofia

1431

Sofia

1606

Sofia

5800

Pleven

6000

Kecskemét

6400

Dimitrovgrad

7002

Rousse

9024

Győr

10000

Zagreb

11650

Mexico City

13901

Binghamton

14050

Mexico City

14610

Mexico City

15009

Beaver

16684

Tipton

27103

Winston-Salem

28304

Fayetteville

28625

Statesville

29464

Mt. Pleasant

30308

Atlanta

31238

Chihuahua City

33021

Hollywood

34070

Durango

45246

Springdale

62250

Cuernavaca

71603

Pine Bluff

73112

Oklahoma City

75093

Plano

85723

Tucson

91307

West Hills

91911

Chula Vista

91978

Spring Valley

97504

Medford

98055

Renton

01015

Guatemala City

06700

Mexico City

15-276

Bialystok

80-757

Gdansk

66-400

Gorzów

31-121

Krakow

50-088

Wroclaw

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00266240 - A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter